Sarepta Therapeutics (SRPT.O) said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie (ABBV.N) executive, will succeed Doug Ingram.
Shares of the company were up nearly 6% in premarket trading.
